Spyre Therapeutics Stock Price, News & Analysis

Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock options for 19,600 shares to one non-executive employee under the 2018 Equity Inducement Plan. The grants were approved on November 3, 2025, have a 10-year term, and an exercise price equal to the $23.78 Nasdaq closing price on November 3, 2025. Vesting is one-fourth on the first anniversary of the employee’s start date and then 1/48th monthly thereafter, subject to continuous service. The options were described as material to the employee’s acceptance of employment under Nasdaq Listing Rule 5635(c)(4).

Spyre Therapeutics (NASDAQ:SYRE) reported Q3 2025 results and program updates on Nov 4, 2025. Key developments include positive Phase 1 interim data for SPY003 (IL-23) showing a ~85-day half-life supporting quarterly or twice‑annual dosing, and interim Phase 1 data for SPY002/SPY072 showing complete TL1A suppression through up to 20 weeks.

The company initiated the SKYWAY Phase 2 basket trial (SPY072) in Sept 2025 and the SKYLINE Phase 2 platform (SPY001/SPY002; SPY003 expected soon). Spyre expects six Phase 2 proof‑of‑concept readouts in 2026. Financings: $316M gross from an underwritten offering and pro forma cash of $782.7M as of Sept 30, 2025, with expected runway into H2 2028.

Spyre Therapeutics (NASDAQ: SYRE) announced positive interim Phase 1 results for SPY003, an extended half-life anti-IL-23 antibody, from a first-in-human randomized, double-blind, placebo-controlled study in 59 healthy volunteers (data cutoff Sept 19, 2025).

Key findings: ~85-day half-life (more than 3x risankizumab), dose-proportional PK, limited intrasubject variability, no serious adverse events, two ≥Grade 2 TEAEs deemed not treatment-related, and no apparent anti-drug-antibody impact on PK. Results support potential quarterly or twice-annual SC maintenance dosing and progression into the SKYLINE Phase 2 platform and additional combination programs.

Spyre Therapeutics (NASDAQ: SYRE) announced that management will participate in three investor conferences in November 2025: the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on Nov 10, 2025 at 10:00 am ET, the Stifel 2025 Healthcare Conference in New York on Nov 11, 2025 at 8:40 am ET, and the Jefferies Global Healthcare Conference in London on Nov 19, 2025 at 8:00 am GMT. Live audio webcasts and replays will be available on the company’s investor events website at https://ir.spyre.com/events-and-presentations.

Spyre Therapeutics (NASDAQ: SYRE) announced poster presentations at ACR Convergence 2025 on Oct 24, 2025 covering interim Phase 1 and preclinical data for SPY072.

Key points: six‑month follow‑up from the Phase 1 study shows SPY072 was reported as well tolerated, demonstrated a differentiated pharmacokinetic profile supporting quarterly (Q3M) or twice‑yearly (Q6M) dosing, and suppressed free TL1A through 20 weeks at the lowest dose. Preclinical rodent data were presented showing anti‑TL1A treatment met or exceeded etanercept efficacy in a collagen‑induced arthritis model. Posters relate to the ongoing SKYWAY Phase 2 basket study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Posters are available via the ACR program.

Spyre Therapeutics (Nasdaq: SYRE) announced the closing of an underwritten public offering on Oct 15, 2025 of 17,094,594 shares of common stock, including the full exercise of a 2,229,729‑share underwriter option, at $18.50 per share. The offering generated approximately $316.2 million in gross proceeds before underwriting discounts, commissions and offering expenses. A Form S‑3 registration (File No. 333‑285341) became effective on Mar 7, 2025. Joint book‑running managers included Jefferies, TD Securities, Leerink Partners and Stifel; Wedbush acted as lead manager.

Spyre Therapeutics (NASDAQ: SYRE) priced an underwritten public offering of 14,864,865 common shares at $18.50 per share, expected to generate approximately $275.0 million in gross proceeds before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 2,229,729 shares at the public offering price.

The offering is expected to close on or about October 15, 2025, subject to customary closing conditions. A registration statement (Form S-3, File No. 333-285341) became effective on March 7, 2025.

Spyre Therapeutics (Nasdaq: SYRE) announced on Oct 13, 2025 that it has commenced an underwritten public offering of shares of common stock and, for certain investors, pre-funded warrants to purchase common stock. All securities in the offering will be sold by Spyre. The company expects to grant underwriters a 30-day option to buy additional shares at the public offering price, less underwriting discount. The offering is subject to market and other conditions, and the final terms will be disclosed in a prospectus supplement filed with the SEC (Form S-3 File No. 333-285341).

Spyre Therapeutics (NASDAQ: SYRE) announced poster presentations at United European Gastroenterology Week (UEGW) 2025, according to the PR dated Oct 5, 2025.

The PR states interim Phase 1 data for SPY002 show it was well tolerated through six months, has a differentiated PK profile that the company says could support quarterly (Q3M) or twice‑yearly (Q6M) dosing, and suppressed free TL1A through 24 weeks. The company also reported preclinical combination data where α4β7 + TL1A, α4β7 + IL‑23, and TL1A + IL‑23 combinations outperformed monotherapies in rodent TNBS colitis models. Posters and session details are available via the UEGW program, per the PR.